Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Defining basal-like breast cancer on clinical specimens
FY 2009-10
Summary
Studies examining the relationship between breast cancer subtype and clinical features (disease onset, progression, outcome, etc.) have shown that molecular classification can predict drug response and patient survival. Of particular interest to doctors and scientists, "basal-like" breast cancers afflict younger women, have worst prognosis and lack targeted therapies. Furthermore, recent evidence indicates that more aggressive second generation chemotherapeutic agents, known as anthracyclines, benefit most breast cancer patients with the exception of basal-like cases. Thus, identification of basal-like cancers has the potential to improve the survival and quality of life of these patients by justifying use of cheaper, less toxic first generation chemotherapies. However, the gene expression profile gold standard for identifying basal-like breast cancers is not feasible for hospital use. As such, analysis of characteristic proteins in tumor samples (via immunohistochemistry) is routinely employed in hospital labs. Five years ago, my supervisor published an immunohistochemistry test for basal-like breast cancer that is now widely used. However, its sensitivity is not optimal (76%) so false negatives limit its clinical utility. To solve this problem, the proposed project aims to identify immunohistochemical markers from the latest gene expression profile data and scientific literature, followed by evaluation of their diagnostic potential in order to build a superior test to define basal-like breast cancer. Subsequent application to clinical trial specimens will confirm which treatments work best for basal-like and the other major breast cancer subtypes. Ultimately, by developing a practical and clinically-accessible assay, more personalized treatment options will be made available for the thousands of women afflicted by breast cancer every year in Canada, limiting unwarranted toxicity while giving each patient the best chance of a cure.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
201548
Name
Won Jennifer R
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Defining basal-like breast cancer on clinical specimens
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biostatistics; Breast Cancer; Chemotherapy; Clinical Outcomes; Clinical Trial; Gene Expression Profile; Immunohistochemistry; Predictive Biomarkers; Prognostic Biomarkers; Tissue Microarray
Abstract
Studies examining the relationship between breast cancer subtype and clinical features (disease onset, progression, outcome, etc.) have shown that molecular classification can predict drug response and patient survival. Of particular interest to doctors and scientists, "basal-like" breast cancers afflict younger women, have worst prognosis and lack targeted therapies. Furthermore, recent evidence indicates that more aggressive second generation chemotherapeutic agents, known as anthracyclines, benefit most breast cancer patients with the exception of basal-like cases. Thus, identification of basal-like cancers has the potential to improve the survival and quality of life of these patients by justifying use of cheaper, less toxic first generation chemotherapies. However, the gene expression profile gold standard for identifying basal-like breast cancers is not feasible for hospital use. As such, analysis of characteristic proteins in tumor samples (via immunohistochemistry) is routinely employed in hospital labs. Five years ago, my supervisor published an immunohistochemistry test for basal-like breast cancer that is now widely used. However, its sensitivity is not optimal (76%) so false negatives limit its clinical utility. To solve this problem, the proposed project aims to identify immunohistochemical markers from the latest gene expression profile data and scientific literature, followed by evaluation of their diagnostic potential in order to build a superior test to define basal-like breast cancer. Subsequent application to clinical trial specimens will confirm which treatments work best for basal-like and the other major breast cancer subtypes. Ultimately, by developing a practical and clinically-accessible assay, more personalized treatment options will be made available for the thousands of women afflicted by breast cancer every year in Canada, limiting unwarranted toxicity while giving each patient the best chance of a cure.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Won, Jennifer R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~